Palczewski, Krzysztof,Maeda, Akiko,Golczak, Marcin
申请号：
AU2015201077
公开号：
AU2015201077A1
申请日:
2015.03.03
申请国别(地区):
AU
年份:
2015
代理人:
摘要：
#$%^&*AU2015201077A120150319.pdf#####Abstract: A method of treating an ocular disorder in a subject associated with aberrant all-trans-retinal clearance in the retina, the method comprising administering to the subject a therapeutically effective amount of a primary amine compound of formula: wherein R1 is an aliphatic and/or aromatic compound the primary amine compound upon administration to the subject forming a reversible Schiff-base with the all-trans-retinal or its metabolite in-chiding A2E and retinal dimer without adversely affecting normal retinoid cycle performance the primary amine compound when administered to a Rdh8-- Abca4-,- mouse increasing the optical coherence tomography score of the mouse to at least about 2.5 and increasing II-ds-retinal amount at least about 30% in comparison to untreated control animal, wherein the primary amine compound is not a local anesthetic, which includes an aromatic amine, that demonstrates sodium channel blockade when administered to the subject. 2218156v1
